Shots:
Tahi and Asud initiated the conversation with an overview of EPKINLYTM (epcoritamab) and its approval by the U.S. FDA to treat R/R DLBCL
They then spoke about the study design and results from the EPCORE NHL-1 P-I/II trial that served as the basis for the U.S. FDA approval of EPKINLY.
EPKINLY is being co-developed and co-commercialized by Genmab and AbbVie. Both companies are evaluating…
Corvus Global is delighted to welcome you to attend the Pharmacovigilance World 2023 scheduled in London, United Kingdom on 01-02 November 2023.
Registration Link - https://corvusglobalevents.com/pharmacovigilance-world-2023/products
Discount code: PV5 (5% Discount)
The Pharmacovigilance World 2023 will provide a platform for the participants to discuss, share and stay updated with present state of affairs in Pharmacovigilance and Drug safety, and…
Shots:
Boaz spoke about the US FDA approval of Evkeeza (evinacumab-dgnb) to treat children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH)
Boaz also talked about the study design of the pivotal pediatric trial evaluating Evkeeza(evinacumab-dgnb) . He then extended his talk on HoFH and how Regeneron is creating awareness about the disease
The…
Do you want to gain a competitive edge and make informed decisions for your healthcare business?
Market research is a crucial process that plays a fundamental role in the success of businesses, organizations, and entrepreneurs alike. It involves gathering and analyzing relevant information about the target market, customers, competitors, and industry trends to make informed…
Shots:
In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, we bring for our readers a concise yet thorough analysis of the drug Ocrevus
Ocrevus is a prescription medicine used to treat adults with relapsing or primary progressive multiple sclerosis including CIS, RRMS, and SPMS
PharmaShots presents…
Are you ready to be part of a global movement to advance cancer research and treatment? This is your chance to connect with leading experts, healthcare professionals, and researchers from around the world.
Conference Series is delighted to welcome you to attend the 23rd World Congress on Cancer and Diagnostics scheduled in Toronto, Canada on…
Shots:
We are delighted to announce that today PharmaShots completes five years. With five years of our service, we got acquainted with the vacillating needs of the industry that kept encouraging us to deliver the best in the market
Today, PharmaShots will take you on a vicarious excursion through our fifth-anniversary video. Throughout the years…
Shots:
Kathleen spoke about the results of a new study published in Advances in Therapy evaluating real-world adherence to SPINRAZA (nusinersen) with its unique dosing schedule among people with spinal muscular atrophy (SMA)
She also talked about the overall adherence rates to nusinersen. She highlighted that adherence was higher during the maintenance phase than the loading phase…
Shots:
Ivy shared details of its collaboration with Intercept Pharmaceuticals and how Intercept is using Komodo’s tech platform and healthcare map for a retrospective real-world study on the long-term outcomes for Ocaliva
She also talked about how pharma companies can utilize Komodo’s technology platform and how it supports rare disease research
The interview gives an…
Shots:
Nabil spoke about the data evaluating Vascepa/Vazkepa and eicosapentaenoic acid in reducing cardiovascular events presented at the ACC.23/WCC
He also told our readers about the new analysis from the REDUCE-IT trial showing the effectiveness of VASCEPA/VAZKEPA in patients with recent acute coronary syndrome
The interview shows how Amarin is developing innovative therapies, increasing the…

